Pulmonology Articles

Pulmonology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lanier B et al. – Add–on omalizumab is effective and well tolerated as maintenance therapy in children (6 to <12 years) with moderate–to–severe persistent allergic (IgE–mediated) asthma whose symptoms are inadequately controlled despite medium to high doses of ICSs.


Related Articles

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09    Relevance Score: 87%

Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09    Relevance Score: 85%

Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09    Relevance Score: 84%

“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09    Relevance Score: 84%

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09    Relevance Score: 83%

Today in Pediatric Pulmonology...keeping you current

Low prevalence of glucose intolerance in racially mixed children with cystic fibrosis
Pediatric Diabetes, 02/09/10

Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
Therapeutics and Clinical Risk Management, 02/09/10

Relationship between infant weight gain and later asthma
Pediatric Allergy and Immunology, 02/09/10

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address